Skip to main content
SpringerLink
Log in

Advances in the pharmacotherapy of Alzheimer's disease

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

The authors reviewed the literature on the agents proposed for the treatment of Alzheimer's disease (AD). Different classes of drugs have been tested for this indication including psychostimulants, anitcoagulants, vasodilators, hyperbaric oxygen, hormones, nootropics, cholinomimetics, monoaminergics and neuropeptides without conclusive evidence of being beneficial for the treatment of this condition. Among the cholinomimetics recent research data seems to indicate that they might produce modest benefits in mild-to-moderate AD patients. Recently, other drugs have also been proposed including neurotrophic factors, phosphatidylserine, argistension converting enzyme (ACE) inhibitors, calcium channel blockers, acetyl-l-carnitine, xanthine derivatives, anti-inflammatory agents, aluminum chelate agents, andd-cycloserine. Of these new strategies few hold promise of more substantial benefits for AD, with the possibility of altering the course of the disease, but these drugs await confirmatory trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agnoli A, Fabbrini G, Fioravanti M et al. (1992) CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur Neuropsychopharmacol 2:31–35

    Google Scholar 

  • Ala T, Romero S, Knight F, Feldt K, Frey WH (1990) GM-1-treatment of Alzheimer's disease. A pilot study of safety and efficacy. Arch Neurol 47:1126–1130

    Google Scholar 

  • Allegro L, Favaretto V, Zilliotto G (1987) Oral phosphatidylserine in elderly patients with cognitive deterioration: an open study. Clin Trials J 24(1):104–108

    Google Scholar 

  • Amaducci L (1988) Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 24:130–134

    Google Scholar 

  • Arnstein AFT, Cai JX, Goldman-Rakic PS (1988) The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side-effects: evidence for alpha-2 receptor subtypes. J Neurosci 8:4287–4296

    Google Scholar 

  • Arregui A, Perry EK, Rossor M et al. (1982) Angiotensin converting enzyme in Alzheimer's disease: increased activity in caudate nucleus and cortical areas. J Neurochem 38:1490–1492

    Google Scholar 

  • Ban TA, Morey L, Aguglia E et al. (1990) Nimodipine in the treatment of old age dementias. Prog Neuro Psychopharmacol Biol Psychiatry 14:525–551

    Google Scholar 

  • Banen DM (1974) An ergot preparation (hydergine) for relief of symptoms of cerebrovascular insufficiency. J Am Geriatr Soc 20:22–24

    Google Scholar 

  • Banfi S, Dorigotti L (1986) Experimental behavioral studies with oxiracetam on different type of chronic cerebral impairment. Clin Neuropharmacol 9 (Suppl 3):519–526

    Google Scholar 

  • Barnes JM, Barnes NM, Costall B et al. (1989) Angiotensin II inhibits the release of (3H) acetylcholine from rat entorhinal cortex in vitro. Brain Res 491:136

    Google Scholar 

  • Beermann B (1993) Side effects of long acting cholinesterase inhibitors. Acta Neurol Scand (Suppl) 149:53–54

    Google Scholar 

  • Bergman I, Brane G, Gottfries CG et al. (1983) Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology 80:279–283

    Google Scholar 

  • Bonnavita E (1986) Study of the efficacy and the stability ofl-acetyl-carnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol 23:511–516

    Google Scholar 

  • Bottini G, Vallar G, Cappa S et al. (1992) Oxiracetam in dementia: a double-blind, placebo-controlled study. Acta Neurol Scand 86:237–241

    Google Scholar 

  • Branconnier RJ, Cole JO, Gardos G (1979) ACTH-4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome. Psychopharmacology 61:161–165

    Google Scholar 

  • Branconnier RJ, Cole JO, Dessain EC et al. (1983) The therapeutic efficacy of piracetam in Alzheimer's disease: preliminary observations. Psychopharmacol Bull 19:726–730

    Google Scholar 

  • Breitner JCS, Gau BA, Welsh KA et al. (1994) Inverse association of antiinflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 44:227–232

    Google Scholar 

  • Brinkman SD, Smith RC, Meyer JS et al. (1982) Lecithin and memory training in suspected Alzheimer's disease. J Gerontol 37:4–9

    Google Scholar 

  • Brousseau T, Legrain S, Berr C et al. (1994) Confirmation of the E4 allele of the apolipoprotein E gene as a risk factor for lateonset Alzheimer's disease. Neurology 44:342–344

    Google Scholar 

  • Bruno G, Mohr E, Gillespie M et al. (1985) RS-86 therapy of Alzheimer's disease. Arch Neurol 43:659–661

    Google Scholar 

  • Bruno G, Mohr E, Gillespie M et al. (1986) Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86. Arch Neurol 43:659–661

    Google Scholar 

  • Burke WJ; Roccaforte WH, Wengel SP et al. (1993)l-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 41:1219–1225

    Google Scholar 

  • Cafarra P, Santamaria V (1987) The effects of phosphatidylserine in patients with mild cognitive decline: an open trial. Clin Trials J 24(1):109–114

    Google Scholar 

  • Caltagirone C, Gainotti G, Masullo C (1982) Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 16:247–249

    Google Scholar 

  • Caltagirone C, Albanese A, Gainotti G et al. (1983) Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 18:143–147

    Google Scholar 

  • Calvani M, Carta A, Caruso G et al. (1992) Action of acetyl-l-carnitine in neurodegeneration and Alzheimer's disease. Ann NY Acad Sci 663:483–486

    Google Scholar 

  • Caputo CB, Salama AI (1989) The amyloid proteins of Alzheimer's diseases as potential targets for drug therapy. Neurobiol Aging 10:451–461

    Google Scholar 

  • Caputo CB, Scott CW, Sobel IR et al. (1992) Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease. Clin Neuropharmacol 15 (Suppl 1):414A-415A

    Google Scholar 

  • Chatellier G, Lacomblez L (1990) Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 300:495–499

    Google Scholar 

  • Chouinard G, Annable L, Ross-Chouinard A et al. (1981) A double-blind, placebo-controlled study of piracetam in elderly psychiatric patients. Psychopharmacol Bull 17(1):129

    Google Scholar 

  • Christie JE, Shering A, Ferguson J et al. (1981) Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50

    Google Scholar 

  • Claus JJ, Ludwig C, Mohr E et al. (1991) Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam. Neurology 41:570–574

    Google Scholar 

  • Corsi P, Coyle JT (1991) Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc Natl Acad Sci USA 88:1793

    Google Scholar 

  • Croisile B, Trillet M, Fondarai J et al. (1993) Long-term and highdose piracetam treatment of Alzheimer's disease. Neurology 43:301–305

    Google Scholar 

  • Croog SH, Sudilovsky A, Levine S et al. (1987) Work performance, absenteeism and antihypertensive medications. J Hypertens 5 (Suppl 1):47–54

    Google Scholar 

  • Crook T, Petrie W, Wells C et al. (1992) Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol Bull 28:61–66

    Google Scholar 

  • Crook T, Wilner E, Rothwell A et al. (1992) Noradrenergic intervention in Alzheimer's disease. Psychopharmacol Bull 28(1): 67–70

    Google Scholar 

  • Cutler NR, Haxby J, Kay AD et al. (1985a) Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures. Arch Neurol 42:744–748

    Google Scholar 

  • Cutler NR, Haxby JV, Narang PK et al. (1985b) Evaluation of an analogue of somatostatin (L363, 586) in Alzheimer's disease. N Engl J Med 312:725

    Google Scholar 

  • Cutler NR, Murphy MF, Nash RJ et al. (1990) Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-l-maleate (HP 029) in Alzheimer's disease: preliminary findigns. J Clin Pharmacology 30:556–561

    Google Scholar 

  • Cutler NR, Fakouhi TD, Smith WT et al. (1993) Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type. J Geriatr Psychiatry Neurol 6:115–119

    Google Scholar 

  • Dal-Bianco P, Maly J, Wober C et al. (1991) Galanthamine treatment in Alzheimer's disease. J Neural Transm Suppl 33:59–63

    Google Scholar 

  • Davidson M, Mohs RC, Hollander E et al. (1987) Lecithin and piraceram in patients with Alzheimer's disease. Biol Psychiatry 22:112–114

    Google Scholar 

  • Davidson M, Stern RG (1991) The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach. Psychiatr Clin North Am 14(2):461–482

    Google Scholar 

  • Davidson M, Zemishlany Z, Mohs RC et al. (1988) 4-Aminopyridine in the treatment of Alzheimer's disease. Biol Psychiatry 23:485–490

    Google Scholar 

  • Davis KL (1989) Toward a therapeutic strategy based on amyloid precursor protein: unanswered questions. Neurobiol Aging 10: 475–8

    Google Scholar 

  • Davis KL, Mohs RC, Davis BM et al. (1980) Human memory and the effects of physostigmine and choline chloride. Psychopharmacol Bull 16(4):27–28

    Google Scholar 

  • Davis KL, Hollander E, Davidson M et al. (1987) Induction of depression with oxotremorine in Alzheimer's disease patients. Am J Psychiatry 144:468–471

    Google Scholar 

  • Davis KL, Thal LJ, Gamzu ER et al. (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 327:1253–1259

    Google Scholar 

  • Dehlin O, Hedenrub B, Jansson P et al. (1985) A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand 71:190–196

    Google Scholar 

  • Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A et al. (1986) Double-blind randomized controlled study of phosphatidylserine in senil-demented patients. Acta Neurol Scand 73:136–140

    Google Scholar 

  • Deyo RA, Straube KT, Disterhoft JF (1989) Nimodipine facilitates associative learning in aging rabbits. Science 243:809–811

    Google Scholar 

  • Ditch M, Kelly FJ, Resnick O (1971) An ergot preparation (hydergine) in the treatment of cerebrovascular disorders in the geriatric patient; double-blind study. J Am Geriatr Soc 19: 208–217

    Google Scholar 

  • Dornbush RL, Volavka J (1976) ACTH 4-10: a study of toxicological and behavioral effects in an aging sample. Neuropsychobiolgy 2:350–360

    Google Scholar 

  • Dornbush RL, Shapiro B, Freedman AM (1981) Effects of an ACTH short chain neuropeptide in man. Am J Psychiatry 138: 962–964

    Google Scholar 

  • Dysken MW, Fovall P, Harris CM et al. (1982) Lecithin administration in Alzheimer dementia. Neurology 32:1203–1204

    Google Scholar 

  • Dysken MW, Katz R, Stallone F et al. (1989) Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology, 21:141

    Google Scholar 

  • Dysken MW, Mendels J, LeWitt P et al. (1992) Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc 40:503–506

    Google Scholar 

  • Eagger SA, Levy R, Sahakian BJ (1991) Tacrine in Alzheimer's disease. Lancet 337:989–992

    Google Scholar 

  • Eagger S, Morant N, Levy R et al. (1992) Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. Br J Psychiatry 160:36–40

    Google Scholar 

  • Ebmeier KP, Hunter R, Curran SM et al. (1992) Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 108:103–109

    Google Scholar 

  • Engel RR, Satzger W, Gunther W et al. (1992) Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol 2:149–155

    Google Scholar 

  • Etienne P, Gauthier S, Dastoor D et al. (1978a) Lecithin in Alzheimer's disease. Lancet 2:1206

    Google Scholar 

  • Etienne P, Gauthier S, Johnson G et al. (1978b) Clinical effects of choline in Alzheimer's disease. Lancet 1:508–509

    Google Scholar 

  • Etienne P, Dastoor D, Gauthier S et al. (1981) Alzheimer's disease: lack of effect of lecithin treatment for 3 months. Neurology 31:1552–1554

    Google Scholar 

  • Farlow M, Gracon SI, Hershey LA et al. (1992) A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 268:2523–2529

    Google Scholar 

  • Ferris H, Sathananthan G, Gershon S et al. (1976) Cognitive effects of ACTH 4-10 in the elderly. Pharmacol Biochem Behav 5(1): 73–78

    Google Scholar 

  • Ferris SH, Reisberg B, Crook T et al. (1982) Pharmacological treatment of senile dementia: choline,l-DOPA, piracetam and choline plus piracetam, In: Corkin S, Davis KL, Growdon JH et al. (eds) Alzheimer's disease: a report of progress. Raven Press, New York, pp 475–481

    Google Scholar 

  • Finali G, Piccirilli M, Oliani C et al. (1991)l-deprenyl therapy improves verbal memory in amnesic Alzheimer patients. Clin Neuropharmacol 14:523–536

    Google Scholar 

  • Fisher LJ, Raymon HK, Gage FH (1993) Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease. Ann NY Acad Sci 695:278–284

    Google Scholar 

  • Fitten LJ, Perryman KM, Gross PL et al. (1990) Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study. Am J Psychiatry 147:239–242

    Google Scholar 

  • Flicker C, Ferris SH, Kalkstein D et al. (1994) A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am J Psychiatry 151:126–129

    Google Scholar 

  • Francis PT, Sims NR, Procter AW et al. (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity-and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 60:1589–1604

    Google Scholar 

  • Friedman E, Sherman KA, Ferris SH et al. (1981) Clinical response to choline plus piracetam in senile dementia: relation to red-cell choline levels. N Engl J Med 304:1490–1491

    Google Scholar 

  • Gauthier S, Bouchard R, Lamontagne A et al. (1990) Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 322:1272–1276

    Google Scholar 

  • Gerin J (1969) Symptomatic treatment of cerebrovascular insufficiency with hydergine. Curr Ther Res 11:539–546

    Google Scholar 

  • Goodnick PJ, Gershon S (1983) Chemotherapy of cognitive disorders. In: Samuel D et al. (eds) Aging of the brain. Raven Press, New York, pp 349–361

    Google Scholar 

  • Goodnick P, Gershon S (1984) Chemotherapy of cognitive disorders in geriatric subjects. J Clin Psychiatry 45:196–209

    Google Scholar 

  • Gottfries CG, Adolfsson R, Aquilonius SM et al. (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4:261

    Google Scholar 

  • Gottfries CG, Nyth AL (1991) Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann NY Acad Sci 640:276–279

    Google Scholar 

  • Gottfries CG, Karlsson I, Nyth AL (1992) Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 6(Suppl 5):55–64

    Google Scholar 

  • Granata Q, Michelle JD (1987) Phosphatidylserine in elderly patients. Clin Trials J 24(1):99–103

    Google Scholar 

  • Green RC, Goldstein FC, Auchus AP et al. (1992) Treatment trial of oxiracetam Alzheimer's disease. Arch Neurol 49:1135–1136

    Google Scholar 

  • Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10:593–602

    Google Scholar 

  • Growdon JH, Corkin S, Huff FJ et al. (1986) Piracetam combined with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 7:269–276

    Google Scholar 

  • Hagg T, Hanthorpe M, Vahlsing HC et al. (1988) Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp Neurol 101: 303

    Google Scholar 

  • Harbaugh RE (1987) Intracerebroventricular cholinergic drug administration in Alzheimer's disease: preliminary results of a double-blind study. J Neural Transm Suppl 24:271–277

    Google Scholar 

  • Harbaugh RE, Reeder TM, Senter HJ et al. (1989) Intracere-broventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study. J Neurosurg 71:481–486

    Google Scholar 

  • Harell LE, Callaway RI, Morere D et al. (1990) The effect of longterm physostigmine administration in Alzheimer's disease. Neurology 40:1350–1354

    Google Scholar 

  • Harris RJ, Branston WM, Symon L et al. (1982) Cerebral ischemia and calcium. Stroke 13:759–766

    Google Scholar 

  • Hefti F (1983) Alzheimer's disease caused by a lack of nerve growth factor? Ann Neurol 13:109–110

    Google Scholar 

  • Hefti F, Schneider LS (1991) Nerve growth factor and Alzheimer's disease. Clin Neuropharmacol 14 (Suppl 1):S62-S76

    Google Scholar 

  • Hefti F, Will B (1987) Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for Alzheimer's disease. J Neural Transm Suppl 24:309–315

    Google Scholar 

  • Henderson VW, Roberts E, Wimer C et al. (1989) Multicenter trial of naloxone in Alzheimer's disease. Ann Neurol 25:404–406

    Google Scholar 

  • Henderson G, Johnson JW, Ascher P (1990) Competitive antagonists and partial agonist at the glycine modulatory site of the mouseN-methyl-d-aspartate receptor. J Physiol 430:189–212

    Google Scholar 

  • Heuser I, Heuser-Link M, Gotthardt U et al. (1993) Behavioral effects of a synthetic corticotropin 4–9 analog in patients with depression and patients with Alzheimer's disease. J Clin Psychopharmacol 13:171–174

    Google Scholar 

  • Heyman A., Schmechel D, Wilkinson W et al. (1987) Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. J Neural Transm Suppl 24:279–286

    Google Scholar 

  • Hoffman D, Wahlber L, Aebischer P (1990) NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Soc Neurosci (Abstr) 16:477

    Google Scholar 

  • Hollander E, Davidson M, Mohs RC et al. (1987) RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 22:1067–1078

    Google Scholar 

  • Hood WF, Compton RP, Monahan JB et al. (1989)d-Cycloserine: a ligand for theN-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91–95

    Google Scholar 

  • Hughes J, Williams J, Currier A (1975) An ergot alkaloid preparation (hydergine) in the treatment of dementia: critical review of literature. J Am Geriat Soc 24:490–497

    Google Scholar 

  • Hyman BT, Eslinger PJ, Damasio AR (1985) Effect of naltrexone on senile dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 48:1169–1171

    Google Scholar 

  • Itil TM, Gopi N, Menon GN (1982) The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Dev Res 2:447–461

    Google Scholar 

  • Itil TM, Menon GN, Songar A et al. (1986) CNS pharmacology and clinical therapeutical effects of oxiracetam. Clin Neuropharmacol 9 (Suppl 3):670–672

    Google Scholar 

  • Izquierdo I (1980) Effect of beta-endorphin and naloxone on acquisition, memory and retrieval of shuttle avoidance and habituation learning in rats. Psychopharmacology 69:111

    Google Scholar 

  • Jellinger K, Flament H, Reiderer P et al. (1980) Levodopa in the treatment of (pre)senile dementia. Ageing Dev 14:253–264

    Google Scholar 

  • Jenike MA, Albert M, Baer L et al. (1990a) Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. J Geriat Psychiat Neurol 3: 13–16

    Google Scholar 

  • Jenike MA, Albert MS, Heller H et al. (1990b) Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. J Clin Psychiatry 51:3–7

    Google Scholar 

  • Jenike MA, Albert MS, Baer L (1990c) Oral physostigmine as treatment for dementia ot the Alzheimer's type: a long-term outpatient trial. Alzheimer Dis Assoc Disord 4:226–231

    Google Scholar 

  • Jennings WG (1972) An ergot alkaliod preparation (hydergine) versus placebo for the treatment of symptoms of cerebrovascular insufficiency: double-blind study. J Am Geriat Soc 20:407–412

    Google Scholar 

  • Jotkowitz S (1983) Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease. Ann Neurol 14:690–691

    Google Scholar 

  • Knapp MJ, Knopman DS, Solomon PR et al. (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271:985–991

    Google Scholar 

  • Koliatsos VE, Price DL, Clatterbuck RE et al. (1993) Neurotrophic strategies for treating Alzheimer's disease: lessons from basic neurobiology and animal models. Ann NY Acad Sci 695:292–299

    Google Scholar 

  • Kruck TP, McLachlan DR (1989) Aluminum as a pathogenic factor in senile dementia of the Alzheimer type: ion-specific chelation. Prog Clin Biol Res 317:1155–1167

    Google Scholar 

  • Lapchak PA (1993) Nerve growth factor pharmacology: application to the treatment of cholinergic neurodegeneration in Alzheimer's disease. Exp Neurol 124:16–20

    Google Scholar 

  • Lawlor BA, Davis KL (1992) Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 31:337–350

    Google Scholar 

  • Lawlor BA, Sunderland T, Mellow AM et al. (1991) A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease. Biol Psychiatry 30:140–144

    Google Scholar 

  • LeVere TE, Brugler T, Sandin M et al. (1989) Recovery of function after brain damage: facilitation by the calcium entry blocker nimodipine. Behav Neurosci 103(3):561–565

    Google Scholar 

  • Levy R (1990) Are drugs targeted at Alzheimer's disease useful? 1. Useful for what? BMJ 300:1131–1132

    Google Scholar 

  • Maina G, Fiori L, Torta R et al. (1989) Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 21:141–145

    Google Scholar 

  • Mangoni A, Grassi MP, Frattola L et al. (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 31:100–107

    Google Scholar 

  • McConnachie RW (1973) A clinical trial comparing “hydergine” with placebo in the treatment of cerebrovascular insufficiency in elderly patients. Curr Med Res Opin 1:463–468

    Google Scholar 

  • McDonald R (1979) Hydergine: a review of 26 clinical studies. Neuropsychopharmacology 12:407–422

    Google Scholar 

  • McGeer PL, Rogers J (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology 42:447–449

    Google Scholar 

  • McLachlan DRC, Dalton AJ, Kruck TPA et al. (1991) Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304–1308

    Google Scholar 

  • Mellow AM, Sunderland T, Cohen RM et al. (1989) Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology 98:403–407

    Google Scholar 

  • Mihara M, Ohnishi A, Tomono Y et al. (1993) Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31:223–229

    Google Scholar 

  • Miller TP, Fong K, Tinklenberg JR (1993) An ACTH-4-9 analog (Org 2766) and cognitive performance: high-dose efficacy and safety in dementia of the Alzheimer's type. Biol Psychiatry 33: 307–309

    Google Scholar 

  • Minthon L, Gustafson L, Dalfelt G et al. (1993) Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 4:32–42

    Google Scholar 

  • Mitchel A, Drachman DA, O'Donnel B et al. (1986) Oral physostigmine in Alzheimer's disease. Neurology 36 (Suppl 1):295

    Google Scholar 

  • Mizuke Y, Yamada M, Kato I et al. (1984) Effects of aniracetam, a nootropic drug, in senile dementia — a preliminary report. Kurume Med J 31:135–143

    Google Scholar 

  • Moglia A, Sinforiani E, Zandrini C et al. (1986) Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study. Clin Neuropharmacol 9 (Suppl 3):573–578

    Google Scholar 

  • Mohr E, Bruno G, Foster N et al. (1986) GABA-agonist therapy for Alzheimer's disease. Clin Neuropharmacol 9(3):257–263

    Google Scholar 

  • Mohr E, Schlegel J, Fabbrine G et al. (1989) Clonidine treatment of Alzheimer's disease. Arch Neurol 46:376–378

    Google Scholar 

  • Molloy DW, Cape RD (1989) Acute effects of oral pyridostigmine on memory and cognitive function in SDAT. Neurobiol Aging 10:199–204

    Google Scholar 

  • Molloy DW, Guyatt GH, Wilson DB et al. (1991) Effect of tetrahydroaminoacridine on cognition, function and bahviour in Alzheimer's disease. Can Med Assoc J 144:29–34

    Google Scholar 

  • Monahan JB, Handelmann GE, Hood WF et al. (1989)d-Cycloserine, a positive modulator of theN-methyl-d-aspartate receptor, enhances performance of learning task in rats. Pharmacol Biochem Behav 34:649–653

    Google Scholar 

  • Mondadori C, Etienne P (1990) Nootropic effects of ACE inhibitors in mice. Psychopharmacology 100:301–307

    Google Scholar 

  • Morgan JM, Routtenberg A (1977) Angiotensin injected into the neostriatum after learning disrupts retention performance. Science 196:87–89

    Google Scholar 

  • Mouradian MM, Mohr E, Williams AJ et al. (1988) No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 38:606–608

    Google Scholar 

  • Mouradian MM, Blin J, Giuffra M et al. (1991) Somatostatin replacement therapy for Alzheimer's dementia. Ann Neurol 30: 610–613

    Google Scholar 

  • Murphy MF, Hardiman ST, Nash RJ et al. (1991) Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease. Ann NY Acad Sci 640:253–262

    Google Scholar 

  • Newhouse PA, Sunderland T, Tariot PN et al. (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175

    Google Scholar 

  • Nyth AL, Gottfries CG (1990) The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 157:894–901

    Google Scholar 

  • Ohnishi A, Mihara M, Kamakura H et al. (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacology 33:1086–1091

    Google Scholar 

  • Olafsson K, Jorgensen S, Jensen HV et al. (1992) Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 85:453–456

    Google Scholar 

  • Olson L (1993) NGF and the treatment of Alzheimer's disease. Exp Neurol 124:5–15

    Google Scholar 

  • Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 4:2745–2752

    Google Scholar 

  • Palmieri G, Palmieri R, Inzoli MR et al. (1987) Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J 24(1):73–83

    Google Scholar 

  • Panella JJ Jr, Blass JP (1984) Lack of clinical benefit from naloxone in a dementia day hospital. Ann Neurol 15:308

    Google Scholar 

  • Parnetti L, Mecocci P, Petrini A et al. (1989) Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group. Neuropsychobiology 22:97–100

    Google Scholar 

  • Parnetti L, Senin U, Carosi M et al. (1993) Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. Clin Ther 15(2):394–406

    Google Scholar 

  • Peabody CA, Thiemann S, Pigache R et al. (1985) Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in patients with dementia. Neurobiol Aging 6:95–100

    Google Scholar 

  • Peabody CA, Davies H, Berger PA et al. (1986) Desamino-d-arginine-vasopressin (DDAVP) in Alzheimer's disease. Neurobiol Aging 7:301–303

    Google Scholar 

  • Peabody CA, Deblois TE, Tinklenberg JR (1986) Thyrotropin-releasing hormone (TRH) and Alzheimer's disease. Am J Psychiatry 143:262–263

    Google Scholar 

  • Peacock ML, Fink JK (1994) ApoE E4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis. Neurology 44:339–341

    Google Scholar 

  • Penn RD, Martin EM, Wilson RS et al. (1988) Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials. Neurology 38:219–222

    Google Scholar 

  • Phelps CH, Gage FH, Growdon JH et al. (1989) Potential use of nerve growth factor to treat Alzheimer's disease. Neurobiol Aging 10:205–207

    Google Scholar 

  • Piccinin GL, Finali G, Piccirilli M (1990) Neuropsychological effects ofl-deprenyl in Alzheimer's type dementia. Clin Neuropharmacol 13:147–163

    Google Scholar 

  • Pomara N, Domino EF, Yoon H et al. (1983) Failure of single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's disease. J Clin Psychiatry 44:293–295

    Google Scholar 

  • Pomara N, Block R, Moore N et al. (1984) Combined piracetam and cholinergic precursor treatment of primary degenerative dementia. IRCS Med Sci 12:388–389

    Google Scholar 

  • Pomara N, Stanley M, Rhiew HB et al. (1988) Loss of the cortisol response to naltrexone in Alzheimer's disease. Biol Psychiatry 23:726

    Google Scholar 

  • Puca FM, Savarese MA, Mirervine MG (1987) Exploratory trial of phosphatidylserine efficacy in mildly demented patients. Clin Trials J 24(1):94–98

    Google Scholar 

  • Puri SK, Hsu RS, Ho I et al. (1989) Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential alzheimer agent. J Clin Pharmacol 29:278–284

    Google Scholar 

  • Puri Sk, Ho I, Hsu R et al. (1990) Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease. J Clin Pharmacol 30:948–955

    Google Scholar 

  • Rai G, Wright G, Scott L et al. (1990) Double-blind, placebo cotrolled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 11:638–647

    Google Scholar 

  • Rainer M, Mark TH, Haushofer A (1989) Galanthaminun hydrobromicum in treatment of senile dementia (Alzheimer's disease). Presented at the Fourth World Conference on Clinical Pharmacology and Therapeutics. Berlin (West), July 28–30

  • Rao DB, Norris JR (1972) A double-blind investigation of hydergine in the treatment of cerebrovascular insufficiency in the elderly. Johns Hopkins Med J 130:317–324

    Google Scholar 

  • Read SL, Frazee J, Shapira J et al. (1990) Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses. Arch Neurol 47:1025–1030

    Google Scholar 

  • Rehman SA (1973) Two trials comparing “hydergine” with placebo in the treatment of patients suffering from cerebrovascular insufficieny. Curr Med Res Opin 1:456–462

    Google Scholar 

  • Rogers J, Kirby LC, Hempelman SR et al. (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609–1611

    Google Scholar 

  • Rosenberg DR, Wright BA, Gershon S (1991) Cognitive enhancering agents for the treatment of senile dementia of the Alzheimer type. Drugs Today 26(7):449–471

    Google Scholar 

  • Sahakian B, Jones G, Levy R et al. (1989) The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797–800

    Google Scholar 

  • Saletu B, Moller HJ, Grunberger J et al. (1990–91) Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology 24:173–184

    Google Scholar 

  • Saletu B, Anderer P, Fischhof PK et al. (1992) EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry 32:668–681

    Google Scholar 

  • Sano M, Bell K, Cote L et al. (1992) Double-blind parallel design pilot study of acetyllevocarnitine in patients with Alzheimer's disease. Arch Neurol 49:1137–1141

    Google Scholar 

  • Satzger W, Bove D, Gerko S et al. (1988) Preliminary results of a six-month double-blind crossover study of phosphatidylserine vs placebo in patients with early senile dementia of Alzheimer's type. Psychopharmacology 96:301

    Google Scholar 

  • Saunders AM, Strittmatter WJ, Schmechel D et al. (1993) Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467–1472

    Google Scholar 

  • Schlegel J, Mohr E, Williams J et al. (1989) Guanfacine treatment of Alzheimer's disease. Clin Neuropharmacol 12:124–128

    Google Scholar 

  • Schmechel D, Schmitt F, Horner J et al. (1984) Lack of effect of oral physostigmine and lecithin in patients with probable Alzheimer's disease. Neurology 34 (Suppl 1):280

    Google Scholar 

  • Seiger a, Nordberg A, von Holst H et al. (1993) Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 57:255–261

    Google Scholar 

  • Senin U, Abate G, Fieschi C et al. (1991) Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): results of a placebo controlled multicentre clinical study. Eur Neuropsychopharmacol 1:511–517

    Google Scholar 

  • Serby M, Resnick R, Jordan B et al. (1986) Naltrexone and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiat 10:587

    Google Scholar 

  • Shore D, Wyatt RJ (1983) Aluminum and Alzheimer's disease. J Nerv Ment Disord 171:553–558

    Google Scholar 

  • Siegfried KR (1991) First clinical impressions with an ACTH analog (HOE 427) in the treatment of Alzheimer's disease. Ann NY Acad Sci 640:280–283

    Google Scholar 

  • Sinforiani E, Agostinis C, Merlo P et al. (1987) Cognitive decline in aging brain: therapeutic approach with phosphatidylserine. Clin Trials J 24(1):115–124

    Google Scholar 

  • Sitaram N, Weingartner H, Gillin JC (1978) Human serial learning: enhancement with arecoline and impairment with scopolamine correlated with performance on placebo. Science 201: 274–276

    Google Scholar 

  • Smith RC, Vroulis G, Johnson R et al. (1984) Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease. Psychopharmacol Bull 20:542–545

    Google Scholar 

  • Soininen H, Koskinen T, Helkala EL et al. (1985) Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog. Neurology 35:1348–1351

    Google Scholar 

  • Sourander LB, Portin R, Molsa P et al. (1987) Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent. Psychopharmacology 91:90–95

    Google Scholar 

  • Spagnoli A, Lucca U, Menasce G et al. (1991) Long-term acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 41: 1726–1732

    Google Scholar 

  • Stegnick A (1972) The clinical use of piracetam, a new nootropic drug, Arzneimforsch (Drug Res) 22:975–977

    Google Scholar 

  • Steiger WA, Mendelson M, Jenkins T et al. (1985) Effects of naloxone in treatment of senile dementia. J Am Geriat Soc 33(2): 155

    Google Scholar 

  • Stern Y, Sano M, Mayeux R (1987) Effects of oral physostigmine in Alzheimer's disease. Ann Neurol 22:306–310

    Google Scholar 

  • Stern Y, Sano M, Mayeux R (1988) Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 38: 1837–1841

    Google Scholar 

  • Sudilovsky A, Cutler NR, Sramek JJ et al. (1993) A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Dis Assoc Disord 7:105–111

    Google Scholar 

  • Svennerholm L, Gottfries CG, Blennow K et al. (1990) Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Acta Neurol Scand 81:48–53

    Google Scholar 

  • Taminga CA, Durso R, Fedio P et al. (1982) Vasopressin studies in Alzheimer's disease. Psychopharmacol Bull 18:48

    Google Scholar 

  • Tariot PN, Cohen RM, Sunderland T et al. (1987)l-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 44:427–433

    Google Scholar 

  • Tariot PN, Sunderland T, Weingartner H et al. (1987) Cognitive effects ofl-deprenyl in Alzheimer's disease. Psychopharmacology 91:489–495

    Google Scholar 

  • Tariot PN, Cohen RM, Welkowitz JA et al. (1988) Multiple-dose arecoline infusions in Alzheimer's disease. Arch Gen Psychiatry 45:901–905

    Google Scholar 

  • Thal LJ, Rosen W, Sharpless NS et al. (1981) Choline chloride fails to improve cognition of Alzheimer's disease. Neurobiol Aging 2:205–208

    Google Scholar 

  • Thibault A (1974) A double-blind evaluation of “hydergine” and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home. Curr Med Res Opin 2:482–487

    Google Scholar 

  • Thompson TL, Filley CM, Mitchell WD et al. (1990) Lack of efficacy of hydergine in patients with Alzheimer's disease. N Engl J Med 323:445–448

    Google Scholar 

  • Tinklenberg JR, Pigache R, Berger PA et al. (1982) Desglycinamide-9-arginine-8-vasopressin (DGAVP, Organon 5667) in cognitively impaired patients. Psychopharmacol Bull 18:202

    Google Scholar 

  • Tollefson GD (1990) Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the managemetn of primary degenerative dementia. Biol Psychiatry 27:1133–1142

    Google Scholar 

  • Triboletti F, Ferri H (1969) Hydergine for treatment of symptoms of cerebrovascular insufficiency. Curr Ther Res 11:609–620

    Google Scholar 

  • Villardita C, Parini J, Grioli S et al. (1986) Clinical and neuropsychological investigations on oxiracetam in patients with mild to moderate dementia. Clin Neuropharmacol 9 (Suppl 14):301–303

    Google Scholar 

  • Villardita C, Grioli S, Salmeri G et al. (1987) Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J 24(1):84–93

    Google Scholar 

  • Villardita C, Grioli S, Lomeo C et al. (1992) Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. Neuropsychobiology 25:24–28

    Google Scholar 

  • Vogel-Scibilia S, Gershon S (1989) An update on cognitive enhancers for the elderly. New Trends in Clin Neuropharmacol 3(4):207–216

    Google Scholar 

  • Watkins PB, Zimmerman HJ, Knapp MJ et al. (1994) Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271:992–998

    Google Scholar 

  • Watson GB, Bolanowski MA, Baganoff MP et al. (1990)d-Cycloserine acts as partial agonist in the glycine modulatory site of the NMDA receptor expressed inXenopus oocytes. Brain Res 510:158–160

    Google Scholar 

  • Weinstein HC, Teunisse S, van Gool WA (1991) Terahydroamino-acridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carriers. J Neurol 238: 34–38

    Google Scholar 

  • Wettstein A (1983) No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol 13:210–212

    Google Scholar 

  • Wettstein A, Spiegel R (1984) Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 84:572–573

    Google Scholar 

  • Williams LR, Varon S, Peterson GM et al. (1986) Continuous infusion of nerve growth factor prevents vasal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 83:9231–9235

    Google Scholar 

  • Winker MA (1994) Tacrine for Alzheimer's disease. Which patient, what dose? JAMA 271:1023–1024

    Google Scholar 

  • Wolters EC, Riekkinen P, Lowenthal A et al. (1990) DGAVP (Org 5667) in early Alzheimer's disease patients: an international double-blind, placebo-controlled, multicenter trial. Neurology 40:1099–1101

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Western Psychiatric Institute and Clinic, University of Pittsburgh, 9811 O'Hara Street, 15213, Pittsburgh, PA, USA

    Jair C. Soares & Samuel Gershon

Authors
  1. Jair C. Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Gershon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soares, J.C., Gershon, S. Advances in the pharmacotherapy of Alzheimer's disease. Eur Arch Psychiatry Clin Nuerosci 244, 261–271 (1994). https://doi.org/10.1007/BF02190379

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02190379

Key words

Search

Navigation